Drugs / ALXN2230
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07352423 | Mar → Dec 2026 expected | — | Alexion Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALXN2230 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07352423 ↗ |
| Route | Subcutaneous | “Participants will receive ALXN2230 via SC injection. Optional cohort will receive ALXN2230 via SC infusion.” NCT07352423 ↗ |